Precision medicine accelerates tuberculosis control and prevention_West China Medical Journal

Authors：

PANG Yu ,  LI Liang

Beijing Chest Hospital, Capital Medical University, Beijing 101149, P. R. China;

Corresponding?author：

LI Liang, Email: liliang69@tb123.org

Keywords：

Precision medicine; Tuberculosis; Prevention

DOI：

10.7507/1002-0179.201807059

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Tuberculosis (TB) is one of the major public health concerns worldwide. Since the development of precision medicine, the filed regarding TB control and prevention has been brought into the era of precision medicine. Although great progress has been achieved in the accurate diagnosis, treatment and management of TB patients, we have to face several challenges. We should seize the opportunity, and develop and improve novel measures in TB prevention on the basis of precision medicine. The accurate diagnosis criteria, treatment regimen and management of TB patients should be carried out according to the standard of precision medicine. We aim to improve the treatment of TB patients and prevent the transmission of TB in the community, thereby contributing to the achievement of the End TB Strategy by 2035.

Citation： PANG Yu, LI Liang. Precision medicine accelerates tuberculosis control and prevention. West China Medical Journal, 2018, 33(8): 921-925. doi: 10.7507/1002-0179.201807059 Copy

1.	Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med, 2015, 372(9): 793-795.
2.	王旭陽, 劉其會, 張文宏. 精準醫療與結核病. 微生物與感染, 2017, 12(6): 328-332.
3.	武愛文, 季加孚. 實施精準醫學的機遇與挑戰. 中華臨床實驗室管理電子雜志, 2015, 3(3): 129-131.
4.	Dorman S. Advances in the diagnosis of tuberculosis: current status and future prospects. Int J Tuberc Lung Dis, 2015, 19(5): 504-516.
5.	Ryu YJ. Diagnosis of pulmonary tuberculosis: recent advances and diagnostic algorithms. Tuberc Respir Dis (Seoul), 2015, 78(2): 64-71.
6.	Ou X, Li Q, Xia H, et al. Diagnostic accuracy of the PURE-LAMP test for pulmonary tuberculosis at the county-level laboratory in China. PLoS One, 2014, 9(5): e94544.
7.	Pang Y, Wang Y, Zhao S, et al. Evaluation of the xpert MTB/RIF assay in gastric lavage aspirates for diagnosis of smear-negative childhood pulmonary tuberculosis. Pediatr Infect Dis J, 2014, 33(10): 1047-1051.
8.	World Health Organization. Definitions and reporting framework for tuberculosis-2013 revision. Geneva: World Health Organization, 2013. http://apps.who.int/iris/bitstream/handle/10665/79199/9789241505345_eng.pdf;sequence=1.
9.	中華醫學會結核病學分會. 中國結核病病理學診斷專家共識. 中華結核和呼吸雜志, 2017, 40(6): 419-425.
10.	張海青, 車南穎. 我國結核病病理學診斷和研究的現狀與展望. 中國防癆雜志, 2014, 36(9): 793-797.
11.	Cattamanchi A, Huang L, Worodria W, et al. Integrated strategies to optimize sputum smear microscopy: a prospective observational study. Am J Respir Crit Care Med, 2011, 183(4): 547-551.
12.	安軍, 逄宇. 重視新型實驗室技術助力菌陰肺結核診斷. 中國防癆雜志, 2018, 40(4): 345-347.
13.	Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis, 2012, 12(1): 103.
14.	World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV: policy guidance. Geneva: World Health Organization, 2015. http://apps.who.int/iris/bitstream/handle/10665/193633/9789241509633_eng.pdf?sequence=1.
15.	Liu C, Zhao Z, Fan J, et al. Quantification of circulating Mycobacterium tuberculosis antigen peptides allows rapid diagnosis of active disease and treatment monitoring. Proc Natl Acad Sci USA, 2017, 114(15): 3969-3974.
16.	Click ES, Murithi W, Ouma GS, et al. Detection of apparent cell-free M. tuberculosis DNA from plasma. Sci Rep, 2018, 8(1): 645.
17.	Che N, Yang X, Liu Z, et al. Rapid detection of cell-free Mycobacterium tuberculosis DNA in tuberculous pleural effusion. J Clin Microbiol, 2017, 55(5): 1526-1532.
18.	Kosaka N, Yoshioka Y, Katsuda T, et al. Exosome in disease biology, diagnosis, and therapy. Inflamm Regen, 2014, 34(5): 233-239.
19.	Smith VL, Cheng Y, Bryant BR, et al. Exosomes function in antigen presentation during an in vivo Mycobacterium tuberculosis infection. Sci Rep, 2017, 7: 43578.
20.	劉君, 裴豪, 蒯守剛, 等. 結核分枝桿菌實驗室耐藥診斷技術進展. 現代預防醫學, 2014, 41(20): 3775-3777.
21.	Pang Y, Dong H, Tan Y, et al. Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China. Sci Rep, 2016, 6: 25330.
22.	Pang Y, Xia H, Zhang Z, et al. Multicenter evaluation of genechip for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol, 2013, 51(6): 1707-1713.
23.	Li Q, Dong HY, Pang Y, et al. Multicenter evaluation of the molecular line probe assay for multidrug resistant Mycobacterium tuberculosis detection in China. Biomed Environ Sci, 2015, 28(6): 464-467.
24.	World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement. (2008-06-27)[2018-07-26]. http://www.who.int/tb/features_archive/policy_statement.pdf.
25.	Zhang Z, Wang Y, Pang Y, et al. Comparison of different drug susceptibility test methods to detect rifampin heteroresistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2014, 58(9): 5632-5635.
26.	Walker TM, Kohl TA, Omar SV, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis, 2015, 15(10): 1193-1202.
27.	Cho HJ, Koh WJ, Ryu YJ, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb), 2007, 87(6): 551-556.
28.	Mahajan R. Bedaquiline: first FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res, 2013, 3(1): 1-2.
29.	Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med, 2012, 366(23): 2151-2160.
30.	Quan D, Nagalingam G, Payne R, et al. New tuberculosis drug leads from naturally occurring compounds. Int J Infect Dis, 2017, 56: 212-220.
31.	Abate G, Hoft DF. Immunotherapy for tuberculosis: future prospects. Immunotargets Ther, 2016, 5: 37-45.
32.	Yang XY, Chen QF, Li YP, et al. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS One, 2011, 6(9): e23826.
33.	Shen H, Min R, Tan Q, et al. The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis. Arch Med Sci, 2015, 11(3): 584-590.
34.	Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science, 2006, 311(5768): 1770-1773.
35.	Getahun H, Matteelli A, Chaisson RE. Latent Mycobacterium tuberculosis infection. N Engl J Med, 2015, 372(22): 2127-2135.
36.	Bhusal Y, Shiohira CM, Yamane N. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents, 2005, 26(4): 292-297.
37.	Liu X, Lewis JJ, Zhang H, et al. Effectiveness of electronic reminders to improve medication adherence in tuberculosis patients: a cluster-randomised trial. PLoS Med, 2015, 12(9): e1001876.
38.	任思沖, 周海琴, 彭萍. 大數據挖掘促進精準醫學發展. 國際檢驗醫學雜志, 2015, 36(23): 3499-3501.
39.	Jaeger S, Karargyris A, Candemir S, et al. Automatic tuberculosis screening using chest radiographs. IEEE Trans Med Imaging, 2014, 33(2): 233-245.

1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med, 2015, 372(9): 793-795.
2. 王旭陽, 劉其會, 張文宏. 精準醫療與結核病. 微生物與感染, 2017, 12(6): 328-332.
3. 武愛文, 季加孚. 實施精準醫學的機遇與挑戰. 中華臨床實驗室管理電子雜志, 2015, 3(3): 129-131.
4. Dorman S. Advances in the diagnosis of tuberculosis: current status and future prospects. Int J Tuberc Lung Dis, 2015, 19(5): 504-516.
5. Ryu YJ. Diagnosis of pulmonary tuberculosis: recent advances and diagnostic algorithms. Tuberc Respir Dis (Seoul), 2015, 78(2): 64-71.
6. Ou X, Li Q, Xia H, et al. Diagnostic accuracy of the PURE-LAMP test for pulmonary tuberculosis at the county-level laboratory in China. PLoS One, 2014, 9(5): e94544.
7. Pang Y, Wang Y, Zhao S, et al. Evaluation of the xpert MTB/RIF assay in gastric lavage aspirates for diagnosis of smear-negative childhood pulmonary tuberculosis. Pediatr Infect Dis J, 2014, 33(10): 1047-1051.
8. World Health Organization. Definitions and reporting framework for tuberculosis-2013 revision. Geneva: World Health Organization, 2013. http://apps.who.int/iris/bitstream/handle/10665/79199/9789241505345_eng.pdf;sequence=1.
9. 中華醫學會結核病學分會. 中國結核病病理學診斷專家共識. 中華結核和呼吸雜志, 2017, 40(6): 419-425.
10. 張海青, 車南穎. 我國結核病病理學診斷和研究的現狀與展望. 中國防癆雜志, 2014, 36(9): 793-797.
11. Cattamanchi A, Huang L, Worodria W, et al. Integrated strategies to optimize sputum smear microscopy: a prospective observational study. Am J Respir Crit Care Med, 2011, 183(4): 547-551.
12. 安軍, 逄宇. 重視新型實驗室技術助力菌陰肺結核診斷. 中國防癆雜志, 2018, 40(4): 345-347.
13. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis, 2012, 12(1): 103.
14. World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV: policy guidance. Geneva: World Health Organization, 2015. http://apps.who.int/iris/bitstream/handle/10665/193633/9789241509633_eng.pdf?sequence=1.
15. Liu C, Zhao Z, Fan J, et al. Quantification of circulating Mycobacterium tuberculosis antigen peptides allows rapid diagnosis of active disease and treatment monitoring. Proc Natl Acad Sci USA, 2017, 114(15): 3969-3974.
16. Click ES, Murithi W, Ouma GS, et al. Detection of apparent cell-free M. tuberculosis DNA from plasma. Sci Rep, 2018, 8(1): 645.
17. Che N, Yang X, Liu Z, et al. Rapid detection of cell-free Mycobacterium tuberculosis DNA in tuberculous pleural effusion. J Clin Microbiol, 2017, 55(5): 1526-1532.
18. Kosaka N, Yoshioka Y, Katsuda T, et al. Exosome in disease biology, diagnosis, and therapy. Inflamm Regen, 2014, 34(5): 233-239.
19. Smith VL, Cheng Y, Bryant BR, et al. Exosomes function in antigen presentation during an in vivo Mycobacterium tuberculosis infection. Sci Rep, 2017, 7: 43578.
20. 劉君, 裴豪, 蒯守剛, 等. 結核分枝桿菌實驗室耐藥診斷技術進展. 現代預防醫學, 2014, 41(20): 3775-3777.
21. Pang Y, Dong H, Tan Y, et al. Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China. Sci Rep, 2016, 6: 25330.
22. Pang Y, Xia H, Zhang Z, et al. Multicenter evaluation of genechip for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol, 2013, 51(6): 1707-1713.
23. Li Q, Dong HY, Pang Y, et al. Multicenter evaluation of the molecular line probe assay for multidrug resistant Mycobacterium tuberculosis detection in China. Biomed Environ Sci, 2015, 28(6): 464-467.
24. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement. (2008-06-27)[2018-07-26]. http://www.who.int/tb/features_archive/policy_statement.pdf.
25. Zhang Z, Wang Y, Pang Y, et al. Comparison of different drug susceptibility test methods to detect rifampin heteroresistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2014, 58(9): 5632-5635.
26. Walker TM, Kohl TA, Omar SV, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis, 2015, 15(10): 1193-1202.
27. Cho HJ, Koh WJ, Ryu YJ, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb), 2007, 87(6): 551-556.
28. Mahajan R. Bedaquiline: first FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res, 2013, 3(1): 1-2.
29. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med, 2012, 366(23): 2151-2160.
30. Quan D, Nagalingam G, Payne R, et al. New tuberculosis drug leads from naturally occurring compounds. Int J Infect Dis, 2017, 56: 212-220.
31. Abate G, Hoft DF. Immunotherapy for tuberculosis: future prospects. Immunotargets Ther, 2016, 5: 37-45.
32. Yang XY, Chen QF, Li YP, et al. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS One, 2011, 6(9): e23826.
33. Shen H, Min R, Tan Q, et al. The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis. Arch Med Sci, 2015, 11(3): 584-590.
34. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science, 2006, 311(5768): 1770-1773.
35. Getahun H, Matteelli A, Chaisson RE. Latent Mycobacterium tuberculosis infection. N Engl J Med, 2015, 372(22): 2127-2135.
36. Bhusal Y, Shiohira CM, Yamane N. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents, 2005, 26(4): 292-297.
37. Liu X, Lewis JJ, Zhang H, et al. Effectiveness of electronic reminders to improve medication adherence in tuberculosis patients: a cluster-randomised trial. PLoS Med, 2015, 12(9): e1001876.
38. 任思沖, 周海琴, 彭萍. 大數據挖掘促進精準醫學發展. 國際檢驗醫學雜志, 2015, 36(23): 3499-3501.
39. Jaeger S, Karargyris A, Candemir S, et al. Automatic tuberculosis screening using chest radiographs. IEEE Trans Med Imaging, 2014, 33(2): 233-245.

Previous Article
惡性腹膜間皮瘤誤診為結核性腹膜炎一例
Next Article
The application of precision medicine in the diagnosis and treatment of tuberculosis

West China Medical Journal

Precision medicine accelerates tuberculosis control and prevention

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content